Catalent, Inc., has signed an exclusive licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) technology platform. The platform has the potential to enable a consistent and cost-effective method to manufacture multiple recombinant antibodies or other recombinant proteins in a single batch culture. Under the licensing agreement, Catalent will continue development work on the platform, both internally and in conjunction with partner-sponsored programs. Catalen...